Reply to "no robust evidence of lumefantrine resistance".
Malaria Branch and President's Malaria Initiative, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA mplucinski@cdc.gov.
Mateusz M
MM
Plucinski
Malaria Branch and President's Malaria Initiative, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Eldin
E
Talundzic
Malaria Branch and President's Malaria Initiative, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Lindsay
L
Morton
National Malaria Control Program, Ministry of Health, Luanda, Angola.
Pedro Rafael
PR
Dimbu
Field Epidemiology and Laboratory Training Program, Ministry of Health, Luanda, Angola.
Aleixo Panzo
AP
Macaia
National Malaria Control Program, Ministry of Health, Luanda, Angola.
Filomeno
F
Fortes
Malaria Branch and President's Malaria Initiative, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Ira
I
Goldman
Malaria Branch and President's Malaria Initiative, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Naomi
N
Lucchi
Malaria Branch and President's Malaria Initiative, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Gail
G
Stennies
Malaria Branch and President's Malaria Initiative, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
John R
JR
MacArthur
Malaria Branch and President's Malaria Initiative, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Venkatachalam
V
Udhayakumar
D037621:Artemisinins / Q000627:therapeutic use*; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D005449:Fluorenes / Q000627:therapeutic use*; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy*; D008297:Male; D010963:Plasmodium falciparum / Q000187:drug effects*; D011804:Quinolines / Q000627:therapeutic use*
D037621:Artemisinins; D004983:Ethanolamines; D005449:Fluorenes; D011804:Quinolines